ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Orchestra BioMed Holdings, Inc. (OBIO) stock declined over -11.26%, trading at $2.60 on NASDAQ, down from the previous close of $2.93. The stock opened at $2.90, fluctuating between $2.60 and $2.90 in the recent session.
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Employees | 56 |
Beta | 0.59 |
Sales or Revenue | $2.76M |
5Y Sales Change% | -0.702% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |